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Summary
Background The anti-progesterone drug mifepristone and the prostaglandin misoprostol can be used to treat missed 
miscarriage. However, it is unclear whether a combination of mifepristone and misoprostol is more effective than 
administering misoprostol alone. We investigated whether treatment with mifepristone plus misoprostol would 
result in a higher rate of completion of missed miscarriage compared with misoprostol alone.
Methods MifeMiso was a multicentre, double-blind, placebo-controlled, randomised trial in 28 UK hospitals. Women 
were eligible for enrolment if they were aged 16 years and older, diagnosed with a missed miscarriage by pelvic 
ultrasound scan in the first 14 weeks of pregnancy, chose to have medical management of miscarriage, and were 
willing and able to give informed consent. Participants were randomly assigned (1:1) to a single dose of oral 
mifepristone 200 mg or an oral placebo tablet, both followed by a single dose of vaginal, oral, or sublingual misoprostol 
800 μg 2 days later. Randomisation was managed via a secure web-based randomisation program, with minimisation 
to balance study group assignments according to maternal age (<30 years vs ≥30 years), body-mass index (<35 kg/m² 
vs ≥35 kg/m²), previous parity (nulliparous women vs parous women), gestational age (<70 days vs ≥70 days), amount 
of bleeding (Pictorial Blood Assessment Chart score; ≤2 vs ≥3), and randomising centre. Participants, clinicians, 
pharmacists, trial nurses, and midwives were masked to study group assignment throughout the trial. The primary 
outcome was failure to spontaneously pass the gestational sac within 7 days after random assignment. Primary 
analyses were done according to intention-to-treat principles. The trial is registered with the ISRCTN registry, 
ISRCTN17405024.
Findings Between Oct 3, 2017, and July 22, 2019, 2595 women were identified as being eligible for the MifeMiso trial. 
711 women were randomly assigned to receive either mifepristone and misoprostol (357 women) or placebo and 
misoprostol (354 women). 696 (98%) of 711 women had available data for the primary outcome. 59 (17%) of 348 women 
in the mifepristone plus misoprostol group did not pass the gestational sac spontaneously within 7 days versus 
82 (24%) of 348 women in the placebo plus misoprostol group (risk ratio [RR] 0·73, 95% CI 0·54–0·99; p=0·043). 
62 (17%) of 355 women in the mifepristone plus misoprostol group required surgical intervention to complete the 
miscarriage versus 87 (25%) of 353 women in the placebo plus misoprostol group (0·71, 0·53–0·95; p=0·021). We 
found no difference in incidence of adverse events between the study groups.
Interpretation Treatment with mifepristone plus misoprostol was more effective than misoprostol alone in the 
management of missed miscarriage. Women with missed miscarriage should be offered mifepristone pretreatment 
before misoprostol to increase the chance of successful miscarriage management, while reducing the need for 
miscarriage surgery.
Funding UK National Institute for Health Research Health Technology Assessment Programme.
Copyright Crown Copyright © 2020 Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
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Introduction
Miscarriage is common, affecting one in five preg­
nancies.1 Miscarriage can cause physical harm, such 
as excessive bleeding and infection,2 and substantial 
psychological harm, including anxiety, depression, and 
post­traumatic stress disorder.3,4 There are two main 
types of miscarriage that require medical intervention, 
missed miscarriage and incomplete miscarriage.5 A 
missed miscarriage, also known as a delayed or silent 
miscarriage, is diagnosed when a non­viable pregnancy 
is identified on ultrasound scan during the first 14 weeks 
of gestation. Often, women who have missed miscarriage 
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are asymptomatic or have small amounts of vaginal 
bleeding or pain before the diagnosis is made.5–7 All 
pregnancy tissue is retained in the uterus in a missed 
miscarriage.5 By contrast, an incomplete miscarriage 
is diagnosed when pregnancy tissue has been partly 
expelled by the uterus.5
Management of first trimester missed miscarriage can 
be done in one of the following three ways: expectant, 
medical, or surgical.6 The recommended first­line treat­
ment for missed miscarriage in the UK is expectant 
management for a duration of 7 to 14 days, during which 
women wait for the uterus to expel the pregnancy tissue 
naturally.5 If expectant management is not successful or 
not acceptable to the woman, then medical management 
is preferred. Medical management expedites the expul­
sion of retained pregnancy tissue with the help of 
medical drugs.5 Medical management is the preferred 
option for many women, and is recommended in 
international clinical guidelines.5,7,8
Misoprostol, a prostaglandin analogue, is commonly 
used for the medical management of miscarriage to 
induce myometrial contractions to aid the expulsion of 
pregnancy tissue.8 However, misoprostol is not always 
effective, and 15–40% of women require an additional 
dose of misoprostol, thus prolonging the duration of 
treatment.9–13 Failure of medical management can result 
in more surgical procedures being done, which can be 
particularly undesirable to women who have chosen to 
have medical management.14,15 To augment the effect of 
misoprostol, a steroidal anti­progesterone called mifepris­
tone is sometimes used in combination. Mifepristone is a 
competitive progesterone receptor antagonist that primes 
the myometrium before prostaglandin exposure.8
The reported effectiveness of combination treatment 
with mifepristone and misoprostol for the medical 
management of missed miscarriage in previous clinical 
trials has ranged from 64% to 84%.16–18 However, given 
the lack of placebo­controlled studies, the usefulness of 
mifepristone in the management of missed miscarriage 
has remained unclear. Standard practice in the UK 
before 2012 was to offer mifepristone plus misoprostol 
for the medical management of missed miscarriage. 
However, in 2012, the National Institute for Health and 
Care Excellence (NICE) guideline (clinical guidance 154) 
recommended not offering mifepristone as a treatment for 
missed or incomplete miscarriage.19 This recom mendation 
was based on the findings of a small randomised controlled 
trial of 115 women, which found no benefit for the use of 
mifepristone and misoprostol versus misoprostol alone.16 
The recommendation to not use combination treatment 
remains in the current 2019 version of the guidance (NICE 
guideline 126).5 Therefore, the standard practice in the UK 
is to offer vaginal misoprostol alone at a dose of 800 μg for 
women diagnosed with incomplete or missed miscarriage.5
Research in context
Evidence before this study
The National Institute for Health and Care Excellence identified 
the effectiveness of a mifepristone and misoprostol 
combination as a research priority, given the paucity of 
evidence on the optimal regimen for medical management of 
missed miscarriage, and the National Institute for Health 
Research subsequently issued a commission call to address this 
issue. We used MEDLINE to search for studies published from 
inception to Dec 15, 2015, in any language using the terms 
“missed miscarriage”, “silent miscarriage”, “delayed 
miscarriage”, “early pregnancy loss”, “miscarriage, medical”, 
“mifepristone”, and “misoprostol”. The abstracts of the studies 
identified by our search were reviewed by two independent 
reviewers to identify trials that compared mifepristone and 
misoprostol in combination with misoprostol alone in the 
medical management of missed miscarriage. We found two 
relevant trials, with a total of 242 participants. Meta-analysis 
indicated that the miscarriage completion rate for mifepristone 
and misoprostol in combination was similar to that of 
misoprostol alone in the medical management of missed 
miscarriage (risk ratio [RR] 0·97, 95% CI 0·82–1·13). However, 
given the imprecision that inevitably accompanies such small 
sample sizes, we could not draw firm inferences. Since our 
review, a Cochrane systematic review published in 2019 
identified three relevant studies, including a total of 
447 women. Meta-analysis of these three trials did not provide 
a clear consensus, resulting in the reviewers calling for further 
research.
Added value of this study
Our study was a large multicentre placebo-controlled trial that 
assessed the effectiveness of the combination of mifepristone 
and misoprostol versus misoprostol alone in the medical 
management of missed miscarriage. We recruited 711 women 
from 28 UK hospitals. We found that mifepristone and 
misoprostol in combination was more effective than misoprostol 
alone in achieving completion of missed miscarriage, with an 
associated reduction in the number of women requiring surgical 
intervention after failed medical management.
Implications of all the available evidence
Our trial found an increase in the 7-day miscarriage completion 
rate and a reduction in the need for surgery with the 
combination of mifepristone and misoprostol when compared 
with mifepristone alone for women with missed miscarriage. 
This finding is consistent with another open-label trial in 
283 patients, which found a higher rate of miscarriage 
completion with combination treatment compared with 
misoprostol alone (RR 1·25, 95% CI 1·09–1·43). Therefore, 
combination treatment should be considered as first-line 
treatment for women who wish to have medical management 
of missed miscarriage. Formal health economic evaluation is 
underway.
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We investigated whether treatment with mifepristone 
in combination with misoprostol would result in a higher 
rate of completion of missed miscarriage compared with 
misoprostol alone.
Methods
Study design and participants
MifeMiso was a multicentre, parallel­group, double­
blind, placebo­controlled randomised effectiveness trial 
in 28 hospitals across the UK. Women were eligible for 
enrolment if they were aged 16 years and older, diagnosed 
with a missed miscarriage by pelvic ultrasound scan in 
the first 14 weeks of pregnancy (by last menstrual period), 
chose to have medical management of miscarriage, 
and were willing and able to give informed consent. 
Diag nosis of missed miscarriage was made by trained 
ultrasonographers in early pregnancy units if a non­
viable pregnancy with the presence of a gestational sac 
was identified on ultrasound scan. Findings had to be 
confirmed by a second trained ultrasonographer or, if a 
second ultrasonographer was unavailable, the ultrasound 
scan was repeated after a further 7 days, as per NICE 
guidance for the diagnosis and initial management of 
miscarriage.5
Women who opted for alternative methods of miscarriage 
management (expectant or surgical), had a diagnosis of 
incomplete miscarriage, life threatening bleeding, contra­
indications to mifepristone or misoprostol, or had partici­
pated in another trial of investigational medicinal products 
during their current pregnancy were excluded from the 
trial.
Research staff from recruiting sites approached women 
diagnosed with missed miscarriage to check eligibility 
for the trial. Verbal and written trial information was 
provided and written consent was obtained from the 
participant. A member of the local research team from 
the recruiting sites gathered and entered baseline data 
into a web­based database, which included the current 
amount of vaginal bleeding using a Pictorial Blood 
Assessment Chart (PBAC) score20 (0–4; 0=no bleeding, 
4=heavy bleeding) and a pregnancy­related pain score 
that was obtained using a visual analogue scale (0–10).
This trial was approved by the UK Medicines and 
Healthcare Products Regulatory Authority, the UK National 
Research Ethics Service Committee (West Midlands—
Edgbaston; reference 17/WM/0017), and the National 
Health Service Research and Development department at 
each participating hospital. The study protocol is available 
online.
Randomisation and masking
Participants were randomly assigned (1:1) to a single 
dose of oral mifepristone 200 mg, followed by a single 
dose of vaginal, oral, or sublingual misoprostol 800 μg 
2 days later, or an oral placebo tablet followed by a single 
dose of vaginal, oral, or sublingual misoprostol 800 μg 
2 days later. Identical mifepristone and matched placebo 
tablets were packaged and supplied by MODEPHARMA 
(London, UK). MODEPHARMA had no role in the 
design of the study, the collection, analysis, or inter­
pretation of the data, or the writing of the report.
Randomisation was managed via a secure web­based 
randomisation program provided by MedSciNet (London, 
UK), with minimisation to balance study group assign­
ments according to maternal age (<30 years vs ≥30 years), 
body­mass index (BMI; <35 kg/m² vs ≥35 kg/m²), 
previous parity (nulliparous women vs parous women), 
gestational age (<70 days vs ≥70 days), amount of bleeding 
(PBAC score;20 ≤2 vs ≥3), and randomising centre. 
Participants, clinicians, pharmacists, trial nurses, and 
midwives were masked to study group assignment 
throughout the trial.
Procedures
Participants were randomly allocated to a single dose of 
oral mifepristone 200 mg or an oral placebo tablet. 
Administration of the oral tablets took place at early 
pregnancy units in the recruiting hospitals. Participants 
then left the early pregnancy unit with instructions to 
return to have their scheduled single dose of vaginal, 
oral, or sublingual misoprostol 800 μg 48 h later. The 
scheduled single dose of misoprostol 800 μg could 
be omitted if the participant had already passed the 
gestational sac after the mifepristone or placebo tablet. 
After 48 h of receiving the single dose of misoprostol 
800 μg, if the participant had no or little bleeding, they 
were asked to contact the research team for consideration 
of a further dose of misoprostol.
Participants were advised to return for a pelvic ultra­
sound scan 7 days after random assignment. If partici­
pants had heavy vaginal bleeding or pain during the course 
of treatment, they were advised to contact their local 
recruiting site to undergo appropriate assessment and 
management. Emergency miscarriage surgery was done if 
clinically indicated (eg, heavy or life threatening vaginal 
bleeding or failure of medical management to expel the 
gestational sac with the participant choosing to undergo 
surgical management). If participants passed the gesta­
tional sac within 7 days after random assignment, they 
were asked to do a urinary pregnancy test 3 weeks after 
random assignment. If the urinary pregnancy test was 
negative, the participant was discharged from the trial. If 
participants failed to spontaneously pass the gestational 
sac within 7 days after random assignment, they were 
managed according to local hospital practice, which 
generally involved offering participants further doses of 
misoprostol 800 μg or surgical management of miscar­
riage after appropriate clinical assessment. Participants 
remained in the trial until they had a negative pregnancy 
test and were discharged from the early pregnancy unit.
Outcome data for participants were collated by research 
team members by reviewing the clinical case notes and 
entering data into a web­based database. Participants 
were invited to take part in in­depth interviews following 
For the study protocol see 
https://www.birmingham.ac.uk/
Documents/college-mds/trials/
bctu/MifeMiso/MifeMiso-
Protocol-v5.0-clean-checked-
for-accessibility.pdf
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the resolution of their miscarriage. The findings from 
this mixed­methods study will be reported separately.
Outcomes
The primary outcome was failure to spontaneously pass 
the gestational sac within 7 days after random assignment. 
This primary outcome was the result of a consensus of 
a national panel of 152 UK health­care practitioners, 
informed by patient and public views. The prespecified 
key secondary outcome was surgical intervention to 
complete the miscarriage up to discharge from hospital 
care. Other secondary outcomes were surgical interven­
tion to complete the miscarriage up to and including 
7 days after random assignment and from 7 days after 
random assignment to discharge from hospital care, need 
for further doses of misoprostol within 7 days after 
random assignment and up to discharge from hospital 
care, diagnosis of infection associated with miscarriage 
requiring outpatient antibiotic treatment, diagnosis of 
infection associated with miscarriage requiring inpatient 
antibiotic treatment, negative pregnancy test result 21 days 
(± 2 days) after random assignment, and duration of 
bleeding as reported by the participant (days). Safety 
outcomes included requirement for blood transfusion, 
side­effects, any serious complications, and death. A 
masked endpoint review committee was convened to 
assess whether the primary outcome had been met for 
participants who did not undergo an ultrasound scan on 
day 6 or 7 and had not already passed their gestational sac 
according to an earlier scan. The masked endpoint review 
committee adhered to a prespecified committee charter. 
In brief, participants who did not undergo ultrasound 
scan on day 6 or 7 were contacted by the central trial 
manage ment team and asked for details regarding the 
course of events, including vaginal bleeding, abdominal 
pain, and passage of pregnancy tissues. After trial 
recruitment was complete, the masked endpoint review 
committee convened to discuss the clinical details of 
each of these participants. The decision of whether the 
primary out come was met needed to be decided 
unanimously by the committee.
Statistical analysis
We calculated that 335 women would need to be 
included in each trial group to provide 90% power to 
detect a minimally important absolute difference of 
ten percentage points between the mifepristone plus 
misoprostol group and the placebo plus misoprostol 
group for the primary outcome of failure to pass 
the gestational sac within 7 days (25% vs 15%) at a 
two­sided α level of 0·05. This minimally important 
difference was chosen on the basis of a national survey 
of health­care practitioners in the UK. The control 
group estimate was based on a systematic review by our 
research team at the time of trial design. We planned 
to include 710 women in the trial to account for an 
expected 5% loss to follow­up.
All analyses were prespecified in a statistical analysis 
plan. All randomly assigned women were included in the 
analysis and were analysed in the group to which they 
were randomly allocated, regardless of treatment received 
(intention­to­treat analysis).
For all binary outcomes, we used a log­binomial regres­
sion model to calculate the adjusted risk ratios (RR) and 
95% CIs. For continuous outcomes, we used a linear 
regression model to estimate adjusted mean differences 
and 95% CIs. All estimates of treatment effects between 
groups were adjusted for the mini misation variables, 
where maternal age, BMI, and gestational age were 
treated as continuous fixed effects, parity and bleeding 
score as categorical fixed effects, and randomising centre 
as a random effect. If covariate adjustment was not 
possible, alternative models were explored. Where 
required, p values from the associated models were 
produced and used to assess statistical significance.
Figure 1: Study flowchart
354 assigned placebo plus
misoprostol
 
349 completed 6–7 day follow-up
5 excluded
 2 lost to follow-up
 3 discontinued study treatment and 
did not wish to attend follow-up  
or for further data to be collected
2595 eligible
 
711 randomised
1884 declined to participate 
2746 women assessed for eligibility
 
357 assigned mifepristone plus 
misoprostol
349 completed 6–7 day follow-up
 
8 excluded
    5 lost to follow-up
    3 discontinued study treatment and 
did not wish to attend follow-up 
or for further data to be collected
 
348 with data available for analysis of 
primary outcome
1 missing primary outcome data
 
348 with data available for analysis of 
primary outcome
1 missing primary outcome data
151 not eligible 
 45 over 14 weeks gestation  
 31 unable to understand English  
 5 previous participation in MifeMiso trial   
 3 contraindication to mifepristone 
 3 life-threatening bleeding  
 2 under 16 years of age   
 1 contraindication to mifepristone and 
misoprostol
 61 other
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We prespecified a hierarchical testing procedure to 
allow for multiple comparisons. The null hypothesis for 
the primary outcome was tested first and if statistically 
significant at the 5% level, the key secondary outcome 
would be tested. Otherwise, no further hypothesis testing 
would be done. For all safety outcomes, to assess any 
signal within specific organ systems, p values are 
presented unadjusted for multiple testing. Results from 
all other secondary outcomes are treated as exploratory 
rather than confirmatory. No adjustments for multiple 
testing were made for CIs.
We analysed the treatment effect for the primary 
outcome in prespecified subgroups defined according to 
maternal age (<30 years vs ≥30 years), BMI (<35 kg/m² vs 
≥35 kg/m²), previous parity (nulliparous women vs parous 
women), gestational age (<70 days vs ≥70 days), and 
amount of bleeding (PBAC score20 ≤2 vs ≥3). The subgroup 
defined by gestational age was prespecified as of special 
interest; the results of other subgroup analyses should 
be treated with caution and used for the purposes of 
hypothesis generation only.21 The effects of these subgroups 
were examined by adding the variables for the interaction 
of subgroup with trial group to the regression model. 
We used a χ² test to determine whether the effects of 
mifepristone and misoprostol or placebo and miso prostol 
differed in the various subgroups. Sensitivity analysis 
consisted of a restricted analysis excluding women for 
whom the primary outcome was determined using 
information from the masked endpoint review committee.
Analyses of principal safety and effectiveness outcomes 
were done on behalf of the data and safety monitoring 
committee by the trial statistician (who remained masked 
to treatment assignments) on two occasions during the 
recruitment period (at 251 patients and 507 patients). 
Because these analyses were done with the Peto 
principle,22 which applies a stringent stopping boundary 
of p<0·001, no adjustment was necessary to the final 
p values to determine significance. All analyses were 
done using SAS version 9.4. The trial is registered with 
the ISRCTN registry, ISRCTN17405024.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Between Oct 3, 2017, and July 22, 2019, 2595 women were 
identified as being eligible for the MifeMiso trial (figure 1). 
711 women were randomly assigned to receive either 
mifepristone and misoprostol (357 women) or placebo 
and misoprostol (354 women). 696 (98%) of 711 women 
had available data for the primary outcome. Demographic 
and baseline characteristics were similar between the 
two trial groups (table 1; appendix p 3).
59 (17%) of 348 women in the mifepristone plus 
misoprostol group did not pass the gestational sac spon­
taneously within 7 days, versus 82 (24%) of 348 women in 
the placebo plus misoprostol group (RR 0·73, 95% CI 
0·54–0·99; p=0·043; table 2).
62 (17%) of 355 women in the mifepristone plus 
misoprostol group of required surgical intervention to 
complete the miscarriage, versus 87 (25%) of 353 women 
in the placebo plus misoprostol group (RR 0·71, 95% CI 
0·53–0·95; p=0·021; table 2). Among women who 
underwent surgery, the most common reason for surgery 
was pregnancy tissue remaining in the uterus, reported 
in 55 (89%) of 62 women in the mifepristone plus 
misoprostol group and 79 (91%) 87 women in the placebo 
plus misoprostol group.
50 (14%) of 357 women in the mifepristone plus 
misoprostol group required further doses of misoprostol 
up to discharge, versus 65 (18%) of 354 women in the 
placebo plus misoprostol group (RR 0·77, 95% CI 
See Online for appendix
Mifepristone plus 
misoprostol (n=357)
Placebo plus 
misoprostol (n=354)
Maternal age, years*
<30 95 (27%) 95 (27%)
≥30 262 (73%) 259 (73%)
Mean (SD) 32·8 (5·6) 32·7 (5·7)
Body-mass index (kg/m²)*
<35 332 (93%) 328 (93%)
≥35 25 (7%) 26 (7%)
Mean (SD) 25·8 (5·6) 26·5 (5·5)
Previous parity*
Nulliparous 167 (47%) 168 (47%)
Parous 190 (53%) 186 (53%)
Gestational age, days*
<70 176 (49%) 175 (49%)
≥70 181 (51%) 179 (51%)
Mean (SD) 70·5 (13·1) 70·7 (13·8)
Amount of bleeding (Pictorial Blood Assessment Chart20 score)†
≤2 351 (98%) 348 (98%)
≥3 6 (2%) 6 (2%)
Ethnicity
White 296 (83%) 280 (79%)
Black 10 (3%) 17 (5%)
Asian 38 (11%) 42 (12%)
Other 12 (3%) 15 (4%)
Pregnancy-related pain 
score at random 
assignment‡
1·0 (1·8) 1·2 (2·0)
Number of gestational sacs
1 351 (98%) 348 (98%)
2 6 (2%) 6 (2%)
Data are n (%) or mean (SD). Missing data are <1% unless otherwise presented. 
Further details of baseline characteristics are given in the appendix (p 3). 
*Minimisation variables. †0–4; 0=no bleeding, 4=heavy bleeding. ‡0–10; 
0 indicates no pain, 10 indicates worst possible pain.
Table 1: Baseline characteristics
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0·55–1·09). The mean time from randomisation to 
discharge was 27·0 days (SD 14·2) in the mifepristone 
plus misoprostol group versus 27·3 days (14·4) in the 
placebo plus misoprostol group.
A detailed description of the interventions is provided 
in the appendix (p 5). 337 (94%) of 357 women in the 
mifepristone plus miso prostol group and 341 (96%) of 
354 women in the placebo plus misoprostol group 
Mifepristone plus 
misoprostol (n=357)
Placebo plus 
misoprostol (n=354)
RR estimate* 
(95% CI)
p value
Primary outcome
Failure to pass the gestational sac spontaneously within 7 days after 
random assignment
59/348 (17%) 82/348 (24%) 0·73 (0·54 to 0·99) 0·043
Key secondary outcome
Surgical intervention to complete the miscarriage up to discharge 62/355 (17%) 87/353 (25%) 0·71 (0·53 to 0·95) 0·021
Other secondary outcomes
Surgical intervention to complete the miscarriage up to and including 
day 7 after random assignment
23/355 (6%) 19/353 (5%) 1·23 (0·68 to 2·21)† ··
Surgical intervention to complete the miscarriage from after day 7 
and up to discharge
39/355 (11%) 68/353 (19%) 0·56 (0·39 to 0·81) ··
Need for further doses of misoprostol within 7 days after random 
assignment
34/356 (10%) 48/354 (14%) 0·71 (0·47 to 1·08) ··
Need for further doses of misoprostol up to discharge 50/357 (14%) 65/354 (18%) 0·77 (0·55 to 1·09) ··
Infection requiring outpatient antibiotic treatment 8/351 (2%) 11/351 (3%) 0·73 (0·29 to 1·82)‡ ··
Infection requiring inpatient antibiotic treatment 5/351 (1%) 4/351 (1%) 1·25 (0·33 to 4·74)‡ ··
Negative pregnancy test result 21 days (±2 days) after random 
assignment
237/308 (77%) 230/302 (76%) 1·03 (0·94 to 1·14)§ ··
Pregnancy test not provided 33 28 ·· ··
Missing 16 24 ·· ··
Duration of bleeding reported by woman, days 16·0 (12·6; 326) 16·3 (15·2; 330) –0·3 (–2·5 to 1·8) ··
Time from random assignment to discharge, days 27·0 (14·2; 340) 27·3 (14·4; 337) ·· ··
Data are n (%), n, or mean (SD; N), unless otherwise indicated. Missing data are <3% unless otherwise presented. RR=risk ratio. *Value <1 favours mifepristone plus 
misoprostol combination group; the RR was adjusted for the following minimisation variables: maternal age, body-mass index, previous parity, gestational age, and amount 
of bleeding; the clustering effect of randomising centres was accounted for by using robust standard errors at the centre level. †Centre removed from the model because of 
non-convergence. ‡Unadjusted model used because of non-convergence. §Poisson model used because of non-convergence.
Table 2: Primary and secondary outcome results
Figure 2: Subgroup analyses
PBAC=Pictorial Blood Assessment Chart.
Gestational age (days)
<70
≥70
Maternal age (years)
<30
≥30
Body-mass index (kg/m²)
<35
≥35
Previous parity
Nulliparous
Parous
Amount of bleeding on PBAC
≤2
≥3
 29/171
 30/177
 8/92
 51/256
 55/323
 4/25
 24/63
 35/185
 59/342
 0/6
 41/174
 41/174
 22/92
 60/256
 73/322
 9/26
 34/164
 48/184
 81/342
 1/16
0·73 (0·48–1·12)
0·72 (0·47–1·12)
0·36 (0·17–0·79)
0·86 (0·61–1·20)
0·76 (0·55–1·04)
0·48 (0·17–1·35)
0·72 (0·45–1·17)
0·73 (0·49–1·08)
0·73 (0·54–0·99)
··
0·97
0·05
0·41
0·98
··
Mifepristone plus
misoprostol
Placebo plus
misoprostol
Number of events/total number Risk ratio (95% CI) pinteraction
Favours mifepristone plus misoprostol Favours placebo plus misoprostol
0·35 0·5 0·75 1·0 1·3 1·5
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adhered to the treatment regi men (appendix p 5). A 
sensitivity analysis excluding the findings of the masked 
endpoint review committee was consistent with the 
findings of the primary analysis (RR 0·75, 95% CI 
0·55–1·02; p=0·062; appendix p 8).
We found no evidence of a subgroup effect according to 
gestational age, which was prespecified as a subgroup 
of special interest (figure 2). We found no evidence 
of a between­group difference in the proportions of 
participants with serious adverse events, which were 
reported in five (1%) of 357 women in the mifepristone 
plus misoprostol group and two (1%) of 354 women in 
the placebo plus misoprostol group. The incidence of 
adverse side­effects and requirement for blood trans­
fusion were also similar in both trial groups. There were 
no deaths in the trial population. All safety outcomes and 
adverse side­effects are reported in the appendix (p 9).
Discussion
Our large multicentre, randomised, double­blind, placebo­
controlled trial showed that the combination treatment of 
mifepristone plus misoprostol resulted in an increase in 
the number of missed miscarriages that were completed 
within 7 days compared with miso prostol alone. Further­
more, fewer incidences of surgical management to 
complete miscarriage were reported in the mifepristone 
plus misoprostol group compared with the misoprostol 
alone group. These findings are consistent with other 
previously published trials.18,23,24 A Cochrane review 
published in 201925 identified three previously published 
trials that evaluated the effectiveness of mifepristone and 
misoprostol versus misoprostol alone in the medical 
management of miscarriage. These trials included smaller 
numbers of participants (60 to 300 participants). Although 
these trials used the same dose of mifepristone as our trial 
(200 mg), the dose of misoprostol varied (400 to 800 μg). 
Additionally, these trials assessed the outcome of 
miscarriage management by varying methods, including 
clinical and ultrasound assessment, and at differing 
timepoints. We updated the Cochrane meta­analysis that 
investigated the effectiveness of mifepristone and 
misoprostol compared with misoprostol alone for the 
medical management of miscarriage to incorporate the 
findings from our trial (figure 3). We found a benefit for 
mifepristone plus misoprostol compared with misoprostol 
alone for the resolution of missed miscarriage (RR 1·15, 
95% CI 1·01–1·30).
Our trial results show the importance of optimising 
the medical management of missed miscarriage using 
the combined mifepristone and misoprostol treatment 
regimen, which improves outcomes and safety by 
increasing the proportion of women who have miscar­
riage resolution and reducing the need for surgical 
management. Women who choose medical management 
of missed miscarriage often wish to have expedited 
treatment and resolution of their miscarriage, while 
avoiding the risks of surgery.26 The risks of miscarriage 
surgery are dependent on the clinical context, the set­
ting in which the procedure is done, the surgeon, and 
available equipment. Complications of miscarriage 
surgery are rare, but can include bleeding, infection, and 
uterine perforation requiring more extensive surgery, 
which carries substantial morbidity.26 Our findings show 
that the combination treatment of mifepristone and 
misoprostol reduces the need for surgery after medical 
management, which could be of great importance to 
women who wish to undergo medical management of 
missed miscarriage.
The combination regimen is also likely to be cost­
effective; we are in the process of a formal cost effec­
tiveness analysis using resource use data collected within 
this trial. Similarly, qualitative interviews were done 
with a maximum variation sample of 42 women who 
participated in the trial to explore their satisfaction 
and experiences. A preliminary analysis of the mixed­
methods work found a preference for active management 
of miscarriage to bring a timely resolution to physical 
symptoms, and women were more likely to express 
satisfaction with medical management. Detailed mixed­
methods findings have been interpreted within the 
context of the clinical findings, and will be reported 
separately.
Figure 3: Updated meta-analysis of mifepristone plus misoprostol compared with misoprostol alone for successful resolution of missed miscarriage
Chu et al (2020)26
Fang et al (2009)23
Schreiber et al (2018)18
Sinha et al (2018)24
Total (95% CI)
Total events
Heterogeneity: τ²=0·01; χ²=9·05, degrees of freedom=3; p=0·03; I²=67%
Test for overall effect: Z=2·12; p=0·03
Mifepristone plus
misoprostol
Events Total
289
23
135
39
486
348
30
148
45
571
Misoprostol
alone
Events Total
266
25
113
26
430
348
30
149
45
572
Weight
37·1%
15·6%
33·2%
14·1%
100·0%
1·09 (1·01–1·17)
0·92 (0·71–1·19)
1·20 (1·08–1·33)
1·50 (1·14–1·97)
1·15 (1·01–1·30)
Risk ratio 
Mantel-Haenszel, 
random (95% CI)
Favours misoprostol alone Favours mifepristone plus misoprostol
0·5 0·7 1·0 1·5 2·0
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The strengths of this study include its multicentre 
approach, generalisability across a range of settings, and 
the placebo­controlled design with high adherence to 
treatment, enhancing internal validity. A pragmatic design 
was used in our study, which also adds to the gener­
alisability of our findings. The route of administration of 
misoprostol reflected standard UK clinical practice and 
NICE guidance for the medical management of missed 
miscarriage.5 Most of our participants received vaginal 
misoprostol and the route of misoprostol administration 
was similar in both trial groups. The primary outcome of 
the MifeMiso trial was carefully selected through a 
consultation and survey of clinicians working with women 
diagnosed with miscarriage and the women themselves 
through patient involvement. We collated near­complete 
data for the primary outcome, which was aided by the use 
of a masked endpoint review committee. The committee 
convened using a strict charter and considered each 
individual participant’s clinical data in turn. Clinical data 
were collected on a standardised case report form and the 
decision as to whether the participant had met the primary 
outcome could only be made unanimously. The sensitivity 
analysis excluding the findings of the masked endpoint 
review committee did not alter the findings of our trial 
and was consistent with the primary analysis.
However, some limitations of our study should also be 
considered. We studied the effect of study drugs in missed 
miscarriage, and therefore, the results are not generalisable 
to patients diagnosed with incomplete miscarriage where 
some pregnancy tissue has already been passed. The 
biological rationale for focusing exclusively on missed 
miscarriage was that the anti­progesterone effect of 
mifepristone was less likely to be relevant in incomplete 
miscarriage, in which the expulsion of pregnancy tissue 
has already begun.27
In conclusion, our trial showed that pretreatment with 
mifepristone followed by misoprostol resulted in a 
higher rate of resolution of missed miscarriage by 7 days 
compared with misoprostol treatment alone. Therefore, 
we recommend that women with missed miscarriage 
should be offered mifepristone pretreatment before 
misoprostol to increase the chance of successful mis­
carriage management, while reducing the need for 
miscarriage surgery. Clinical guidelines should be 
updated in light of this evidence.
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